close

Enter

Log in using OpenID

Oral Biologics Market Enhancement in Medical Sector 2018 to 2026

embed
Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn’s
Oral Biologics Market Estimated to Record Highest
CAGR by 2026
Oral Biologics Market by Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor
Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist,
Somatostatin Analogue, and Others), by Disease Indication (Diabetes,
Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic
Constipation (CIC), and Others (Inflammatory Bowel Disease (IBD),
Hypoparathyroidism, and Others)), by Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North
America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size,
Share, Outlook, and Opportunity Analysis, 2018-2026
Biological drugs refer to therapeutic products derived from living organisms or contain components of
living organisms. Biological drugs are widely used in the treatment of number of diseases including
diabetes, plaque psoriasis, arthritis, Crohn’s disease, and ulcerative colitis. Oral biologics products refer
to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are
administrated by parental route and only guanylate cyclase-c agonist class of drug is approved oral
biological in market.
Ask For Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/989
However, key players in the market are involved in development of orally administered glucagon-like
peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone
for different indications.
Market Dynamics
Frequent research and development activities by key players for the development of novel oral
biologics products and launch them in market is expected to boost global oral biologics market growth
over the forecast period. For instance, Allena Pharmaceuticals, Inc., a U.S.-based biopharmaceutical
company, is involved in development of Reloxaliase, a non-absorbed, orally-administered enzyme for
treatment of hyperoxaluria. Currently (June 2019), Reloxaliase is in Phase 2 clinical trial.
Furthermore, key players in the market are involved in strategic partnership and mergers for
development of novel oral biologics products and gain its approval. Such strategic partnerships are
expected to drive global oral biologics market growth. For instance, in December 2017, Rani
Therapeutics and Shire Plc. collaborated to conduct research and evaluate the application of RaniPill
technology for the oral delivery of factor VIII therapy for Hemophilia A patients
In January 2017, Enteris BioPharma, Inc. and Ferring Pharmaceuticals entered into license agreement
to leverage Enteris proprietary oral drug delivery platform Peptelligence, to develop an oral
formulation of a peptide-based injectable therapeutic developed by Ferring. Such strategies among key
players may lead to development of novel oral biologics, which in turn is expected to drive global oral
biologics market growth over the forecast period.
The global oral biologics market size was valued at US$ 834.3 Mn in 2018, and is expected to witness
a CAGR of 32.8% during the forecast period (2018 – 2026).
Increasing partnerships and collaborations by market players is expected to create conducive
environment for global oral biologics market growth
Increasing number of strategic moves such as collaborations and innovations by key players is an
important factor driving global oral biologics market growth in near future.
For instance, in 2016, Rani Therapeutics announced collaboration with Medimmune, a research and
development subsidiary of AstraZeneca, to evaluate Rani Therapeutics’ novel oral drug delivering
platform. This collaboration is expected to facilitate feasibility studies of drugs and test biologic
molecules in the area of metabolic disease, to evaluate oral delivery of molecules. The objective of this
collaboration is to deliver biologics orally, in order to increase compliance and improve patients’ lives
globally.
Get The PDF Brochure of This Report @
https://www.coherentmarketinsights.com/insight/request-pdf/989
Key players operating in the global oral biologics market include Novo Nordisk A/S, Biocon Limited,
Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere
Technologies, Inc., Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.
North America is expected to hold dominant position in the market, owing to presence of major
players and frequent research by them
The U.S. is expected to be most lucrative market for oral biologics in North America, as it is the biggest
pharmaceutical market with high presence of major players. Furthermore, high healthcare expenditure,
healthcare awareness, and high adoption rate of novel drugs make the U.S. most prominent market for
oral biologics.
Key players in the market are focusing on gaining the U.S. FDA approval for their oral biologics and
launch them in the market. For instance, in March 2019, Novo Nordisk A/S submitted two New Drug
Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for oral semaglutide, the oncedaily glucagon-like peptide-1 (GLP-1) receptor agonist in a pill.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran298   documents Email
Document
Category
Health and Medicine
Views
1
File Size
382 KB
Tags
market
1/--pages
Report inappropriate content